Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Taiwan Otsuka Pharm. Co., Ltd
Age
20–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Outpatients, either gender, 20-65 years of age
Patients diagnosed with major depressive disorder as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), who fulfill both the following criteria:
* Having at least one and no more than three inadequate responses of antidepressants
* HAM-D17 score ≥ 14
Willing and able to comply with the study procedure and sign a written informed consent
You may not be if
Females who are pregnant/lactating or planning to be pregnant
Presence of personality disorder cluster B (dramatic, emotional or erratic disorders) or any psychotic symptomatology in the current depressive episode based on Investigators judgment
History of organic mental disorder within 1 year prior to the screening visit
Acute risk of suicide attempts within 3 months prior to the initiation of study treatment (HAM D-17 score item 3 ≥ 3)
Electroconvulsive therapy (ECT) for current episode
Past exposure to aripiprazole treatment or any investigational product (including drug and invasive medical device) within 4 weeks prior to the initiation of study treatment
History of substance / alcohol abuse within 1 year prior to the screening visit
Patient with any medical or psychotic feature, including the presence of significant abnormal laboratory values, which is considered not suitable for this study by Investigator
Clareo Health | Aripiprazole for the Augmentation of Antidepressant Therapy
